PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy after surgery may keep rare skin cancer at bay
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug pembrolizumab can prevent Merkel cell carcinoma from returning after it has been surgically removed. About 280 adults with stage I–III Merkel cell cancer will receive either pembrolizumab or standard observation. The goal is…
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 10, 2026 13:26 UTC
-
New hope for kidney transplant patients with cancer: drug combo aims to fight tumors without losing the donated kidney
Disease control OngoingThis early-stage study tests whether a mix of three drugs—tacrolimus, nivolumab, and ipilimumab—can shrink or control certain skin cancers in people who have had a kidney transplant. The main goal is to see if the cancer responds without causing the body to reject the transplante…
Matched conditions: PATHOLOGIC STAGE III CUTANEOUS MERKEL CELL CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 01, 2026 18:04 UTC